Home
Products
Ginsenoside Rb3
| Product Name | Ginsenoside Rb3 |
| Price: | $51 / 20mg |
| Catalog No.: | CN08040 |
| CAS No.: | 68406-26-8 |
| Molecular Formula: | C53H90O22 |
| Molecular Weight: | 1079.27 g/mol |
| Purity: | >=98% |
| Type of Compound: | Triterpenoids |
| Physical Desc.: | Powder |
| Source: | The roots of Panax ginseng C. A. Mey. |
| Solvent: | DMSO, Pyridine, Methanol, Ethanol, etc. |
| SMILES: | OC[C@H]1O[C@@H](O[C@H]2CC[C@]3([C@H](C2(C)C)CC[C@@]2([C@@H]3C[C@@H](O)[C@H]3[C@@]2(C)CC[C@@H]3[C@](O[C@@H]2O[C@H](CO[C@@H]3OC[C@H]([C@@H]([C@H]3O)O)O)[C@H]([C@@H]([C@H]2O)O)O)(CCC=C(C)C)C)C)C)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O |
| Contact us | |
|---|---|
| First Name: | |
| Last Name: | |
| E-mail: | |
| Question: | |
| Description | Ginsenoside Rb3 is extracted from steamed Panax notoginseng. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC50 of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA. |
| Target | NF-κB:8.2 μM (IC50, in 293T cell lines) COX-2 iNOS |
| In Vitro | Ginsenoside Rb3 (0.1-10 μM) is tested for inhibition of tumor necrosis factor-α (TNF)-induced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) luciferase reporter activity using a human kidney 293T cell-based assay. Ginsenoside Rb3 shows the significant activity with an IC50 of 8.2 μM. Ginsenoside Rb3 also inhibits the induction of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) messenger Ribonucleic acid (mRNA) in a dose-dependent manner after HepG2 cells have been treated with TNF-α (10 ng/mL)[1]. Ginsenoside Rb3 (0.1-10 μM) significantly increases cell viability and inhibits lactate dehydrogenase (LDH) release in a dose-dependent manner. PC12 cell viability as determined by MTT reduction is also markedly decreased after the cell is exposed to oxygen and glucose deprivation (OGD)/OGD-Rep. But, when the cells are pretreated with Ginsenoside Rb3 (0.1, 1, and 10 μM), OGD/OGD-Rep induced cell toxicity is significantly attenuated, which is concentration-dependently attenuated by Ginsenoside Rb3 treatment. The viabilities are raised to 52.8%±5.6%, 64.6%±5.7%, and 76.4%±8.8%, respectively, compared with the control group[2]. |
| In Vivo | Ginsenosides Rb3 is a major compound isolated from Gynostemma pentaphyllum that holistically improves gut microenvironment and induces anti-polyposis in ApcMin/+ mice. Six-weeks-old mice are subjected to Rb3 treatment, before the appearance of the intestinal polyps. All the mice are monitored for food intake, water consumption, and weight changes. Throughout the experiment, no Rb3/Rd-associated weight loss in mice is observed. In addition, none of the treated mice show variations in food and water consumption. Whereas, the number and size of the polyps are effectively reduced by Rb3 treatments[3]. |
| Cell Assay | NGF-differentiated PC12 cells are plated at a density of 1.0×105 cells/mL 2 days before each experiment. To initiate OGD, the cell culture medium is removed and replaced with the glucose-free DMEM, then the cells are incubated at 37°C in an oxygen-free chamber (95% N2 and 5% CO2) for 4 h (OGD), and the change in oxygen levels of the culture medium are monitored during incubation in oxygen-free chamber. Following OGD, glucose is added to normal levels (final concentration: 4.5 mg/mL) and cells are incubated under normal growth conditions (95% air and 5% CO2) for additional 24 h as OGD-reperfusion (OGD-Rep). Ginsenoside Rb3 (0.1, 1, 10 μM) is added to the culture 24 h before OGD treatment and throughout the OGD reperfusion. The control culture is always maintained in normal DMEM and put in the incubator under normal conditions[2]. |
| Animal Admin | Mice[3] Heterozygous male ApcMin/+ (C57BL/6J-ApcMin/+) mice are used. Total 32 male ApcMin/+ mice (aged 6 weeks) are divided into three groups; 10 mice in the control group and 22 mice equally divided for Rb3 and Rd treatments. The mice are daily gavage with a single dose of Ginsenoside Rb3 or Rd at 20 mg/kg, or solvent control. The treatments are carried out for 8 consecutive weeks. |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 1117.1±65.0 °C at 760 mmHg |
| Flash Point | 629.4±34.3 °C |
| Exact Mass | 1078.592407 |
| PSA | 357.06000 |
| LogP | 4.73 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Storage condition | 2-8°C |